Compare Vaxcyte Inc. Common Stock (PCVX) vs Viavi Solutions Inc. Common Stock (VIAV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Viavi Solutions Inc. Common Stock — how do they compare? Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B), while Viavi Solutions Inc. Common Stock trades at $37.33 (market cap $10.15B). The key difference: Vaxcyte Inc. Common Stock and Viavi Solutions Inc. Common Stock are close in size by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Viavi Solutions Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Viavi Solutions Inc. Common Stock for 6 Days on average.
| PCVX | VIAV | |
|---|---|---|
Market Cap | $10.51B | $10.15B |
Volume | 2,644,694 | 4,601,222 |
Sector | Health | Technology |
52-Week High | $73.82 | $55.33 |
52-Week Low | $40.32 | $13.01 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.14B | $10.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VIAVI Solutions (VIAV) trades at $41.28, down 1.13% on the day, with mixed technical signals showing bearish overall momentum but bullish moving averages. The company demonstrates strong revenue growth with fiscal 2026 revenue reaching $1.52B (up 40% YoY) and has beaten earnings estimates for three consecutive quarters. Recent developments include a U.S. Army contract for defense testing and expanded partnerships in network validation, positioning VIAV for growth in AI data center and defense markets.
While analyst consensus remains strongly bullish with a $60.25 price target (78.95% buy ratings), investors face risks from negative net income margins (-2%) and elevated valuation metrics (P/S 6.24, EV/EBITDA 60.68). The stock's outlook depends on continued execution in high-growth segments and margin improvement to justify current valuations amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Viavi Solutions Inc. Common Stock
Viavi Solutions provides network testing, monitoring, and optical technologies. Its products help communications providers, equipment makers, and enterprises build and maintain networks.
Read more on VIAV →
